- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Akoya Biosciences is a medical instruments & supplies business based in the US. Akoya Biosciences shares (AKYA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.85 – a decrease of 0.7% over the previous week. Akoya Biosciences employs 330 staff and has a trailing 12-month revenue of around $93.2 million.
Our top picks for where to buy Akoya Biosciences stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Akoya Biosciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AKYA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Akoya Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Akoya Biosciences stock price (NASDAQ: AKYA)
Use our graph to track the performance of AKYA stocks over time.Akoya Biosciences shares at a glance
Latest market close | $2.85 |
---|---|
52-week range | $1.88 - $6.31 |
50-day moving average | $2.73 |
200-day moving average | $3.50 |
Wall St. target price | $5.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-1.17 |
Is it a good time to buy Akoya Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Akoya Biosciences price performance over time
Historical closes compared with the close of $2.9 from 2024-10-28
1 week (2024-10-22) | 1.05% |
---|---|
1 month (2024-09-30) | 6.62% |
3 months (2024-07-30) | 17.41% |
6 months (2024-04-30) | -24.08% |
1 year (2023-10-30) | -14.71% |
---|---|
2 years (2022-10-28) | -78.79% |
3 years (2021-10-29) | 13.25 |
5 years (2019-10-26) | N/A |
Akoya Biosciences financials
Revenue TTM | $93.2 million |
---|---|
Gross profit TTM | $43.4 million |
Return on assets TTM | -18.09% |
Return on equity TTM | -128.2% |
Profit margin | -64.74% |
Book value | $0.45 |
Market Capitalization | $142.1 million |
TTM: trailing 12 months
Akoya Biosciences share dividends
We're not expecting Akoya Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
Akoya Biosciences share price volatility
Over the last 12 months, Akoya Biosciences's shares have ranged in value from as little as $1.88 up to $6.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akoya Biosciences's is 1.364. This would suggest that Akoya Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Akoya Biosciences's beta into context you can compare it against those of similar companies.
- Neurocrine Biosciences (NBIX.US): 0.364
- Geron Corporation (GERN.US): 0.501
- Rigel Pharmaceuticals (RIGL.US): 0.935
Akoya Biosciences overview
Akoya Biosciences, Inc. , a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Frequently asked questions
nullWhat percentage of Akoya Biosciences is owned by insiders or institutions?
Currently 11.091% of Akoya Biosciences shares are held by insiders and 66.247% by institutions. How many people work for Akoya Biosciences?
Latest data suggests 330 work at Akoya Biosciences. When does the fiscal year end for Akoya Biosciences?
Akoya Biosciences's fiscal year ends in December. Where is Akoya Biosciences based?
Akoya Biosciences's address is: 100 Campus Drive, Marlborough, MA, United States, 01752 What is Akoya Biosciences's ISIN number?
Akoya Biosciences's international securities identification number is: US00974H1041
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question